<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02048917</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13-MULTI-13-KCTN-1301</org_study_id>
    <secondary_id>KCTN-1301</secondary_id>
    <nct_id>NCT02048917</nct_id>
  </id_info>
  <brief_title>Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies</brief_title>
  <official_title>Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kentucky Lung Cancer Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find an optimal smoking cessation strategy in patients&#xD;
      undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky&#xD;
      by delivering high quality smoking cessation to all enrolled patients. This study will also&#xD;
      examine the feasibility of routinely implementing an array of smoking cessation strategies&#xD;
      for this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in the study will be placed in one of twelve treatment arms. Subjects in&#xD;
      each of the twelve treatment regimens will receive either varenicline or bupropion or&#xD;
      long-acting nicotine replacement therapy, with or without use of supplemental nicotine&#xD;
      replacement therapy, and in combination with either standard of care smoking cessation&#xD;
      counseling or high intensity/motivational smoking cessation counseling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2014</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette use</measure>
    <time_frame>8 weeks</time_frame>
    <description>Seven day point prevalence of cigarette use confirmed with CO testing at eight weeks.</description>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>High Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + Long Acting NRT + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + bupropion + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + bupropion + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + varenicline + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + varenicline + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + Long Acting NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + Long Acting NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Intensity Counseling + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Intensity Counseling + varenicline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + Long Acting NRT + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + bupropion + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + bupropion + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + varenicline + PRN NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + varenicline + PRN NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + Long Acting NRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Intensity Counseling + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Intensity Counseling + varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + Long Acting NRT + PRN NRT</intervention_name>
    <description>High Intensity Counseling + Long Acting NRT + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + bupropion + PRN NRT</intervention_name>
    <description>High Intensity Counseling + bupropion + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + bupropion + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + varenicline + PRN NRT</intervention_name>
    <description>High Intensity Counseling + varenicline + PRN NRT</description>
    <arm_group_label>High Intensity Counseling + varenicline + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + Long Acting NRT</intervention_name>
    <description>High Intensity Counseling + Long Acting NRT</description>
    <arm_group_label>High Intensity Counseling + Long Acting NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + bupropion</intervention_name>
    <description>High Intensity Counseling + bupropion</description>
    <arm_group_label>High Intensity Counseling + bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Counseling + varenicline</intervention_name>
    <description>High Intensity Counseling + varenicline</description>
    <arm_group_label>High Intensity Counseling + varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + Long Acting NRT + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + Long Acting NRT + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + bupropion + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + bupropion + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + bupropion + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + varenicline + PRN NRT</intervention_name>
    <description>Low Intensity Counseling + varenicline + PRN NRT</description>
    <arm_group_label>Low Intensity Counseling + varenicline + PRN NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + Long Acting NRT</intervention_name>
    <description>Low Intensity Counseling + Long Acting NRT</description>
    <arm_group_label>Low Intensity Counseling + Long Acting NRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + bupropion</intervention_name>
    <description>Low Intensity Counseling + bupropion</description>
    <arm_group_label>Low Intensity Counseling + bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Intensity Counseling + varenicline</intervention_name>
    <description>Low Intensity Counseling + varenicline</description>
    <arm_group_label>Low Intensity Counseling + varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age.&#xD;
&#xD;
          -  Patient with newly diagnosed or recurrent, histologic diagnosis of any of the&#xD;
             following tobacco related malignancies:&#xD;
&#xD;
               1. Lung or Bronchus cancer or Head &amp; Neck, cancers (all sites).&#xD;
&#xD;
               2. Esophagus, Stomach, Pancreas, Kidney, Urinary Bladder, Colon, Rectum, Cervix,&#xD;
                  Vulvar, Vaginal&#xD;
&#xD;
               3. Carcinoma in situ undergoing definitive surgical resection or treatment (ex:&#xD;
                  radiation of the larynx, and gynecologic tract hysterectomy, vulvectomy - except&#xD;
                  gynecologic patients undergoing ablative or local excisional therapies [laser&#xD;
                  ablation,cervical conization, LEEP].&#xD;
&#xD;
          -  Having smoked at least 1 cigarette within 4 weeks of study enrollment.&#xD;
&#xD;
          -  Having at least a 10-pack year history of cigarette smoking.&#xD;
&#xD;
          -  Having smoked at least one cigarette within 1 month of cancer diagnosis.&#xD;
&#xD;
          -  Life expectancy is greater than 1 year.&#xD;
&#xD;
          -  Patient has an AUDIT score of &lt; 10.&#xD;
&#xD;
          -  Patient has ECOG Performance Status of &lt;=2.&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to provide signed&#xD;
             written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine.&#xD;
&#xD;
          -  History of suicide attempt or preparation for attempt within the past 10 years.&#xD;
&#xD;
          -  C-SRSS Baseline/Screening:&#xD;
&#xD;
               1. Patient response of &quot;Yes&quot; to any question except question 1.&#xD;
&#xD;
               2. Patient response of &quot;Yes&quot; to any question in column one (lifetime), except&#xD;
                  question 1, is not exclusionary unless judged by the investigator to be&#xD;
                  significant in ideation, intensity, behavior or attempts, and precludes&#xD;
                  participation.&#xD;
&#xD;
          -  Hospitalized for psychiatric illness within the past two years.&#xD;
&#xD;
          -  History of Bipolar disorder.&#xD;
&#xD;
          -  Currently taking Bupropion for depression.&#xD;
&#xD;
          -  Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks.&#xD;
&#xD;
          -  History of eating disorder such as anorexia or bulimia.&#xD;
&#xD;
          -  Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis&#xD;
&#xD;
          -  History of epilepsy or seizure disorder.&#xD;
&#xD;
          -  Active severe kidney or liver disease.&#xD;
&#xD;
          -  Women must not be pregnant or lactating. Women of reproductive-potential must have&#xD;
             negative serum or urine pregnancy test within 7 days prior to study enrollment and&#xD;
             agree to use method of contraception during and for 30 days following last cessation&#xD;
             drug dose.&#xD;
&#xD;
          -  Patients within three months of a myocardial infarction.&#xD;
&#xD;
          -  Patients with unstable angina or serious arrhythmia.&#xD;
&#xD;
          -  Patients with psychiatric disability judged by the investigator to be clinically&#xD;
             significant so as to preclude informed consent or compliance with drug intake.&#xD;
&#xD;
          -  Patient taking varenicline or bupropion within one month of study enrollment.&#xD;
&#xD;
          -  Participation in any other investigational drug study within 4 weeks of study&#xD;
             enrollment.&#xD;
&#xD;
          -  Currently enrolled in other professional tobacco cessation therapeutic intervention.&#xD;
&#xD;
          -  Enrollment in a concurrent cancer therapeutic trial will require prior review and&#xD;
             approval by the study site PI to determine that there are no drug interactions&#xD;
             concerns.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Valentino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King's Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hardin Memorial Health Cancer Care Center</name>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <zip>42701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARH Cancer Center</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Cancer Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexington Veterans Affair Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky, Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claire Regional Medical Center</name>
      <address>
        <city>Morehead</city>
        <state>Kentucky</state>
        <zip>40351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Owensboro Health</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2014</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Joseph Valentino</investigator_full_name>
    <investigator_title>Study Chair</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Cessation</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Counseling</keyword>
  <keyword>Tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

